Get the Stockscreener App
3.25
1.52%
-0.05
Grace Therapeutics Inc stock is traded at $3.25, with a volume of 65,911.
It is down -1.52% in the last 24 hours and down -2.99% over the past month.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
See More
Previous Close:
$3.30
Open:
$3.27
24h Volume:
65,911
Relative Volume:
1.12
Market Cap:
$44.94M
Revenue:
-
Net Income/Loss:
$-10.31M
P/E Ratio:
-4.2208
EPS:
-0.77
Net Cash Flow:
$-12.65M
1W Performance:
-0.31%
1M Performance:
-2.99%
6M Performance:
-1.22%
1Y Performance:
+0.00%
1-Day Range:
$3.23
$3.34
1-Week Range:
$3.1739
$3.40
52-Week Range:
$1.75
$4.965
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-322-1602
Address
103 CARNEGIE CENTER, PRINCETON
Compare GRCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
3.25 | 44.72M | 0 | -10.31M | -12.65M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | TD Cowen | Buy |
| Sep-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jan-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-29-19 | Initiated | B. Riley FBR | Buy |
| Jul-18-19 | Initiated | Oppenheimer | Outperform |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Grace Therapeutics Inc Stock (GRCE) Latest News
Can Grace Therapeutics Inc. Regain Momentum After Breakdown2025 Technical Overview & Precise Trade Entry Recommendations - beatles.ru
Volume spikes in Grace Therapeutics Inc. stock – what they meanPortfolio Growth Summary & Low Drawdown Trading Techniques - Newser
Watch for Trend Continuation in Grace Therapeutics Inc. Next WeekMarket Movers & Verified Swing Trading Watchlist - newsyoung.net
How to forecast Grace Therapeutics Inc. trends using time seriesJuly 2025 Trends & Verified Momentum Watchlists - Newser
When is the best time to exit Grace Therapeutics Inc.July 2025 Intraday Action & Precise Entry and Exit Recommendations - Newser
Grace Therapeutics Inc. Breaks Losing Streak — Is the Trend ReversingWeekly Profit Recap & AI Powered Market Entry Ideas - beatles.ru
Using Bollinger Bands to evaluate Grace Therapeutics Inc.Quarterly Profit Report & Weekly High Conviction Ideas - Newser
How Grace Therapeutics Inc. stock performs during market volatilityJuly 2025 Levels & Real-Time Buy Signal Alerts - Newser
Reversal indicators forming on Grace Therapeutics Inc. stockQuarterly Performance Summary & Low Risk High Win Rate Picks - Newser
Should you wait for a breakout in Grace Therapeutics Inc.Quarterly Earnings Summary & Weekly Momentum Stock Picks - Newser
Custom strategy builders for tracking Grace Therapeutics Inc.2025 Earnings Surprises & Verified High Yield Trade Plans - Newser
Multi asset correlation models including Grace Therapeutics Inc.2025 Retail Activity & Accurate Buy Signal Notifications - Newser
Developing predictive dashboards with Grace Therapeutics Inc. data2025 Market Sentiment & Risk Adjusted Buy and Sell Alerts - Newser
What candlestick patterns are forming on Grace Therapeutics Inc.2025 Trade Ideas & AI Based Buy/Sell Signal Reports - Newser
Applying Elliott Wave Theory to Grace Therapeutics Inc.Earnings Performance Report & Risk Controlled Stock Pick Alerts - Newser
Why Grace Therapeutics Inc. is moving todayQuarterly Portfolio Report & Long-Term Growth Portfolio Plans - Newser
Grace Therapeutics Inc. recovery potential after sell offQuarterly Market Summary & Daily Oversold Stock Bounce Ideas - Newser
Using economic indicators to assess Grace Therapeutics Inc. potentialPortfolio Return Report & Smart Money Movement Alerts - Newser
How to track smart money flows in Grace Therapeutics Inc.Gap Down & Weekly Setup with High ROI Potential - Newser
Is Grace Therapeutics Inc.’s ROE strong enoughEarnings Trend Report & Low Risk Entry Point Guides - newsimpact.co.kr
Will Grace Therapeutics Inc. Hold Gains Into Close2025 Stock Rankings & Safe Capital Growth Trade Ideas - beatles.ru
Predicting Grace Therapeutics Inc. trend using moving averagesWatch List & Daily Stock Trend Watchlist - Newser
Candlestick signals on Grace Therapeutics Inc. stock todayTrade Risk Assessment & Long-Term Safe Return Strategies - Newser
Backtesting results for Grace Therapeutics Inc. trading strategiesEarnings Risk Summary & Daily Technical Forecast Reports - Newser
Grace Therapeutics Inc. stock chart pattern explainedMarket Weekly Review & Daily Stock Trend Watchlist - Newser
Grace Therapeutics Inc.’s volatility index tracking explainedPortfolio Risk Report & High Return Trade Opportunity Guides - Newser
Visual trend scoring systems applied to Grace Therapeutics Inc.2025 Market Outlook & Daily Profit Maximizing Trade Tips - Newser
Is Grace Therapeutics Inc. meeting your algorithmic filter criteriaWeekly Trend Summary & Low Risk Entry Point Guides - Newser
Leading vs lagging indicators on Grace Therapeutics Inc. performanceQuarterly Growth Report & Accurate Intraday Trading Signals - Newser
Ranking Grace Therapeutics Inc. among high performing stocks via toolsQuarterly Profit Review & Short-Term High Return Ideas - Newser
Grace Therapeutics Reports Q2 2025 Earnings and Strategic Focus - MSN
Grace Therapeutics Inc Stock (GRCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):